scispace - formally typeset
Z

Zhijian Cao

Researcher at Wuhan University

Publications -  175
Citations -  4033

Zhijian Cao is an academic researcher from Wuhan University. The author has contributed to research in topics: Peptide & Scorpion toxin. The author has an hindex of 32, co-authored 143 publications receiving 3334 citations.

Papers
More filters
Journal ArticleDOI

Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders

TL;DR: The results show that the rs242941 G/G genotype and homozygous GAG haplotype of the three single-nucleotide polymorphisms (SNPs) are associated with fluoxetine therapeutic response in MDD patients of high-anxiety (HA).
Journal ArticleDOI

Structural Basis of a Potent Peptide Inhibitor Designed for Kv1.3 Channel, a Therapeutic Target of Autoimmune Disease

TL;DR: The design of a new peptide inhibitor that is potent and selective for Kv1.3, and the successful design of ADWX-1 suggests that rational design based on the structural model of the peptide-channel complex should accelerate the development of diagnostic and therapeutic agents for human channelopathies.
Journal ArticleDOI

Hg1, Novel Peptide Inhibitor Specific for Kv1.3 Channels from First Scorpion Kunitz-type Potassium Channel Toxin Family *

TL;DR: The first scorpion Kunitz-type potassium channel toxin family with three groups and seven members is identified, of which a novel inhibitor, Hg1, is specific for Kv1.3 channel, and their structural and functional diversity strongly suggest that Kunitzer-type toxins are a new source to screen and design potential peptides for diagnosing and treating Kv 1.3-mediated autoimmune diseases.
Journal ArticleDOI

Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses.

TL;DR: Evidence is provided that host defense peptides from scorpion venom can be modified for antiviral activity by rational design and represents a practical approach for developing broad-spectrum antiviral agents, especially against RNA viruses.